Portal de investigación
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML).
Datos básicos
Documentos
- No hay documentos
Grupos
Financiadores - Promotores
APTOSE BIOSCIENCES INC.
Cita
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML). (HM-FLTI-101). APTOSE BIOSCIENCES INC. 2023-2024. IP:PAU MONTESINOS FERNÁNDEZ.